Marshall Wace’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Marshall Wace’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-410,558	Closed	-$283K	–	3087
2020 Q4	$283K	Buy	+410,558	New	+$874K	﹤0.01%	1667

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Marshall Wace's BMY.RT Position: Q4 2020 in Review

Marshall Wace sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 1,998,539 shares — an estimated $4.26M sold.

Marshall Wace first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $30.5M in Q1 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

Marshall Wace reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
Marshall Wace sold 1,998,539 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $4.26M.
Marshall Wace first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
Marshall Wace's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $30.5M in Q1 2020.
546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on Marshall Wace's 13F filing for Q4 2020, filed 16 Feb 2021.